Honsawek Sittisak, Tanavalee Aree, Sakdinakiattikoon Manoon, Chayanupatkul Maneerat, Yuktanandana Pongsak
Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Clin Biochem. 2009 Jun;42(9):808-12. doi: 10.1016/j.clinbiochem.2009.02.002. Epub 2009 Feb 13.
The purposes of this study were to examine osteopontin levels in both plasma and synovial fluid of patients with primary knee osteoarthritis (OA) and to investigate their relationship with severity of the disease.
Thirty-two patients aged 53-83 years with knee OA and 15 healthy controls were enrolled in this study. Anteroposterior knee radiographs were taken to determine the disease severity of the affected knee. The radiographic grading of OA in the knee was performed by using the Kellgren-Lawrence criteria. Osteopontin levels in the plasma and synovial fluid were measured using enzyme-linked immunosorbent assay.
The mean plasma osteopontin concentration of the knee OA patients was significantly higher compared with that of healthy controls (168.8+/-15.6 vs 67.2+/-7.7 ng/mL, P<0.0001). Osteopontin levels in synovial fluid were significantly higher with respect to paired plasma samples (272.1+/-15.0 vs 168.8+/-15.6 ng/mL, P<0.001). In addition, plasma osteopontin levels showed a positive correlation with synovial fluid osteopontin levels (r=0.373, P=0.035). Subsequent analysis showed that plasma osteopontin levels significantly correlated with severity of disease (r=0.592, P<0.001). Furthermore, the synovial fluid levels of osteopontin also correlated with disease severity (r=0.451, P=0.01).
The data suggest that osteopontin in plasma and synovial fluid is related to progressive joint damage in knee OA. Osteopontin may serve as a biochemical marker for determining disease severity and could be predictive of prognosis with respect to the progression of knee OA.
本研究旨在检测原发性膝关节骨关节炎(OA)患者血浆和滑液中的骨桥蛋白水平,并探究其与疾病严重程度的关系。
本研究纳入了32例年龄在53 - 83岁的膝关节OA患者和15名健康对照者。拍摄膝关节正位X线片以确定患侧膝关节的疾病严重程度。采用Kellgren-Lawrence标准对膝关节OA进行影像学分级。使用酶联免疫吸附测定法测量血浆和滑液中的骨桥蛋白水平。
膝关节OA患者的平均血浆骨桥蛋白浓度显著高于健康对照者(168.8±15.6 vs 67.2±7.7 ng/mL,P<0.0001)。与配对的血浆样本相比,滑液中的骨桥蛋白水平显著更高(272.1±15.0 vs 168.8±15.6 ng/mL,P<0.001)。此外,血浆骨桥蛋白水平与滑液骨桥蛋白水平呈正相关(r = 0.373,P = 0.035)。后续分析表明,血浆骨桥蛋白水平与疾病严重程度显著相关(r = 0.592,P<0.001)。此外,滑液中骨桥蛋白水平也与疾病严重程度相关(r = 0.451,P = 0.01)。
数据表明,血浆和滑液中的骨桥蛋白与膝关节OA的关节渐进性损伤有关。骨桥蛋白可作为确定疾病严重程度的生化标志物,并可能预测膝关节OA进展的预后。